Triple
T22796776
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CDK6 |
E564269
|
entity |
| Predicate | regulatedBy |
P86
|
FINISHED |
| Object | p16INK4A |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: p16INK4A | Statement: [CDK6, regulatedBy, p16INK4A]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: p16INK4A Context triple: [CDK6, regulatedBy, p16INK4A]
-
A.
CDKN2A (p16INK4A)
chosen
CDKN2A (p16INK4A) is a tumor suppressor gene encoding a cyclin-dependent kinase inhibitor that controls cell cycle progression and is frequently inactivated in human cancers.
-
B.
CDKN2B (p15INK4B)
CDKN2B (p15INK4B) is a cyclin-dependent kinase inhibitor tumor suppressor protein that controls cell cycle progression by inhibiting CDK4/6 activity.
-
C.
CDKN2C (p18INK4C)
CDKN2C (p18INK4C) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
-
D.
CDKN2D (p19INK4D)
CDKN2D (p19INK4D) is a cyclin-dependent kinase inhibitor that helps control cell cycle progression by inhibiting CDK4/6 activity and acting as a tumor suppressor.
-
E.
CDK4
CDK4 is a cyclin-dependent kinase that regulates cell cycle progression and is a key therapeutic target in certain cancers.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458185f88190b0045227ee420411 |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17cd9b3c0819096050f43a829ec0d |
completed | April 29, 2026, 3:36 a.m. |
Created at: April 17, 2026, 3:30 p.m.